Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Finished Goods: 2024

  • Whitehawk Therapeutics' Finished Goods was N/A to $1.8 million in Q4 2024 from the same period last year, while for Dec 2024 it was $1.8 million, marking a year-over-year change of. This contributed to the annual value of $1.8 million for FY2024, which is N/A change from last year.
  • Per Whitehawk Therapeutics' latest filing, its Finished Goods stood at $1.8 million for Q4 2024.
  • Whitehawk Therapeutics' Finished Goods' 5-year high stood at $1.8 million during Q4 2024, with a 5-year trough of $1.8 million in Q4 2024.
  • Over the past 1 years, Whitehawk Therapeutics' median Finished Goods value was $1.8 million (recorded in 2024), while the average stood at $1.8 million.